AC 105
Alternative Names: AC-105; PEG-magnesium; Pegylated-magnesium; Polyethylene-glycol-magnesiumLatest Information Update: 20 Jul 2015
Price :
$50 *
At a glance
- Originator Medtronic
- Developer Acorda Therapeutics
- Class Magnesium compounds; Neuroprotectants; Polyethylene glycols
- Mechanism of Action Nervous system modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Spinal cord injuries
Most Recent Events
- 01 May 2015 Acorda Therapeutics completes a phase II trial in Spinal cord injuries in USA and Canada (NCT01750684)
- 01 Feb 2015 Acorda Therapeutics terminates its licensing agreement with Medtronic (Acorda Therapeutics 10-K, February 2015)
- 17 Jul 2013 Phase-II clinical trials in Spinal cord injuries in Canada (IV)